Skip to main content
Year archive

BioInvent International — 2025 filings

All 39 regulatory filings released by BioInvent International (BINV) in 2025, sourced directly from the official regulator.

39 Filings
2025 Period
2025 filings (39)
Filing Released Lang
BioInvent presenterar imponerande responsdata från den pågående fas 2a-studien av trippelkombinationen BI-1206, rituximab och Calquence i r/r NHL på ASH 2025
Regulatory Filings
2025-12-08 Swedish
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025
Regulatory Filings
2025-12-08 English
BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025
Regulatory Filings
2025-12-07 English
BioInvent presenterar lovande tidiga fas 2a-data på ASH 2025 för BI-1808 som monoterapi för behandling av CTCL
Earnings Release Q4 2025
2025-12-07 Swedish
BioInvent presenterar uppdaterade fas 2a monoterapidata på ASH 2025 gällande BI-1808 för behandling av CTCL
Regulatory Filings
2025-11-03 Swedish
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025
Regulatory Filings
2025-11-03 English
BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025
Regulatory Filings
2025-11-03 English
BioInvent kommer att presentera tidiga fas 2a-data på ASH 2025 från den pågående studien med en trippelkombination av BI-1206, rituximab och Calquence i r/r NHL
Regulatory Filings
2025-11-03 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report 9M 2025
2025-10-29 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report 9M 2025
2025-10-29 English
BioInvent Announces Board of Directors Update
Board/Management Information
2025-09-02 English
BioInvent offentliggör förändring i styrelsen
Board/Management Information
2025-09-02 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-26 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-26 English
BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical Programs and Enhance Value Creation
Regulatory Filings
2025-08-26 English
BioInvent gör strategiska portföljförändringar för att accelerera ledande kliniska program och skapa ökat värde
Regulatory Filings
2025-08-26 Swedish
BioInvent presenterar lovande fas 2a-monoterapidata för BI-1808 i CTCL på EHA 2025
Earnings Release Q2 2025
2025-06-12 Swedish
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025
Investor Presentation
2025-06-12 English
XOMA Royalty förvärvar mezagitamab royalty- och milstolpsrättigheter av BioInvent International för upp till 30 miljoner USD
Capital/Financing Update
2025-05-27 Swedish
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD 30 Million
M&A Activity
2025-05-27 English
BioInvent presenterar ytterligare fas 2a-data för BI-1808 monoterapi i CTCL på EHA 2025
Regulatory Filings
2025-05-14 Swedish
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of non-Hodgkin's lymphoma
Regulatory Filings
2025-05-14 English
Uppdatering från BioInvents fas 2a-trippelkombinationsstudie med BI-1206, rituximab och Calquence för behandling av non-Hodgkins lymfom
Earnings Release Q2 2025
2025-05-14 Swedish
BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA 2025
Investor Presentation
2025-05-14 English
Beslut på BioInvents årsstämma 2025
AGM Information
2025-04-29 Swedish
Resolutions at BioInvent’s Annual General Meeting 2025
AGM Information
2025-04-29 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Q1 2025
2025-04-29 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Q1 2025
2025-04-29 English
Annual Report (ESEF) 2024
Annual Report (ESEF) FY 2024
2025-04-04 Swedish
Notice to Annual General Meeting in BioInvent International AB
AGM Information
2025-03-25 English
Kallelse till årsstämma i BioInvent International AB
AGM Information
2025-03-25 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report FY 2024
2025-02-27 Swedish
Earnings Release 2024
Earnings Release FY 2024
2025-02-27 English
BioInvent announces promising initial efficacy data from triple combination arm of BI-1206, rituximab and Calquence for the treatment of non-Hodgkin's lymphoma
Regulatory Filings
2025-01-08 English
BioInvent tillkännager lovande initiala effektdata från trippelkombinationsarmen av BI-1206, rituximab och Calquence i non-Hodgkins lymfom
Earnings Release Q1 2025
2025-01-08 Swedish
BioInvent announces promising initial efficacy data from triple combination arm of BI-1206, rituximab and Calquence for the treatment of non-Hodgkin's lymphoma
Earnings Release Q1 2025
2025-01-08 English
BioInvent tillkännager lovande initiala effektdata från trippelkombinationsarmen av BI-1206, rituximab och Calquence i non-Hodgkins lymfom
Earnings Release Q1 2025
2025-01-08 Swedish
BioInvent tillkännager lovande data för BI-1910 som monoterapi från fas 1-studie i solida tumörer
Regulatory Filings
2025-01-08 Swedish
BioInvent announces promising data for BI-1910 as single agent from Phase 1 study in solid tumors
Regulatory Filings
2025-01-08 English